DIGI-INTERNATIONAL
Digi International® , (NASDAQ: DGII, www.digi.com ), a leading global provider of Internet of Things (IoT) connectivity products and services, today announced it has appointed ISMOsys its pan-European sales representative covering the DACH region, Nordics, Italy, France, and the U.K.
Under the agreement, ISMOsys will represent and promote a broad range of Digi’s product portfolio, including Digi ConnectCore® and Digi XBee® RF modules, and DC-ME, NetSilicon, and Rabbit Semiconductor products portfolios. In addition, ISMOsys will offer a wide range of complementary support services.
Digi’s communications products and services help customers create, deploy, and manage mission-critical connectivity in the most demanding settings. Digi’s full range of highly integrated and reliable embedded and RF modules are ideal for industrial, medical, transit, retail, smart city, and utility applications.
“We are very enthusiastic about this new relationship with Digi International and the opportunities to leverage the synergies between our organizations,” comments ISMOsys President Roberto Blanco. “Digi is the ideal partner to help us support our clients who provide connectivity products and solutions. Their technology leadership and continuous growth are remarkable and we’re proud to contribute to this upward trend.”
“As one of the few truly pan-European sales representatives of electronic solutions and components, ISMOsys is well-positioned to extend Digi’s reach in promoting the most reliable embedded and RF-based IoT solutions for a broad range of applications to a wide customer base,” says Paul Norbury, Digi’s Senior Director of EMEA OEM solutions sales. “ISMOsys is renowned for its great, deep and enduring customer relationships, market knowledge, and broad application understanding – attributes that are ideal for bringing Digi’s superior OEM products to that wider audience.”
About ISMOsys
ISMOsys (Integrated Sales Marketing Operations Systems) is a pan-European representative company, comprised of commercial, sales, and technical expertise, acquired by Astute Electronics in April 2021. It represents major semiconductor and electronics component manufacturers throughout Europe, providing unparalleled support to design houses, designers, and engineers, and supporting advances in design through strong relationships with both manufacturers and designers. Its collaboration with leading distributors and industry partners allows the company to drive sales and revenues for partners. With regional offices and representation throughout Europe, ISMOsys’s localized approach means expertise in each territory and personal service to design houses, designers, and engineers.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products, and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com or call 877-912-3444 (U.S.) or 952-912-3444 (International).
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005348/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
FieldBee Vision wins Gold for Digital Technology Innovation at LAMMA 20269.1.2026 05:25:00 CET | Press release
FieldBee, the European leader in high-quality, easy-to-use and affordable precision agriculture technologies, proudly announces that FieldBee Vision has earned global recognition, becoming the Gold Winner in the Digital Technology Innovation of the Year category at the LAMMA Innovation Awards 2026. Lamma Show is the UK’s premier agricultural machinery, technology and equipment innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107606411/en/ FieldBee wins the LAMMA Innovation Award 2026 for Digital Technology Innovation of the Year for the FieldBee Vision (VisionSteer & VisionPro) system FieldBee Vision is part of the newly launched myFieldBee ecosystem, built to unify FieldBee’s precision farming tools and designed to connect navigation, autosteering, ISOBUS into one unified platform that supports planning, execution, monitoring and reporting. FieldBee Vision, the first modular retrofit agricultural vision system,
Survey Finds Over 70% of Chinese Doctors Recommend “AI Doctor Services” Like Ant Group’s AQ for Everyday Health Needs9.1.2026 04:31:00 CET | Press release
A recent survey by Life Times, a well-known Chinese public health media outlet, shows that AI doctor services are broadly supported by doctors in China. Among 500 physicians from the country’s top-tier (tertiary) hospitals, more than 70% said they would recommend AI doctor services to patients for everyday health questions and routine health management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108456917/en/ Ant Group’s AI-native health app AQ is designed to address common, everyday health concerns and support healthy habit formation. Ant Group’s AQ was the most frequently recommended platform in the survey. The latest figures show that, as of January 2026, the app had accumulated 30 million monthly active users and answers over 10 million health-related questions daily, making it China’s leading AI-native health app. AQ—known in Chinese as Ant A-Fu—is an AI-native health app launched by Ant Group in June 2025. Desig
OPPO Joins VVC Advance Patent Pool as a Licensee and Extends HEVC Advance License9.1.2026 03:00:00 CET | Press release
Access Advance LLC and Guangdong OPPO Mobile Telecommunications Corp., Ltd. (OPPO) today announced that OPPO has joined the VVC Advance Patent Pool as a Licensee and renewed its HEVC Advance License. OPPO, one of the world's largest smartphone manufacturers with operations in more than 70 countries, has been a valued participant in Access Advance's HEVC patent pool since 2020, and more recently joined the Advance Video Distribution Patent (VDP) Pool as a Licensor. These latest agreements mark a new milestone in a broad and deepening relationship between the two companies, with OPPO now participating across all three of Access Advance's video codec licensing programs. The VVC Advance Patent Pool licenses patents essential to the VVC/H.266 standard, which delivers remarkable improvement of video compression performance over HEVC, enabling higher-quality video experiences including 4K, 8K, and HDR content with faster downloads and lower latency. The pool currently includes over 4,500 worl
Cessna Citation CJ3 Gen2 Enters Into Service, Delivering the Most Significant Gen2 Updates to Date8.1.2026 22:30:00 CET | Press release
The Cessna Citation CJ3 Gen2 has entered into service, setting a new standard for the Citation Gen2 family. Launch customers and longtime Citation owners Dave Mecartney and Shannon Day took delivery of their new aircraft this week. Mecartney—an experienced aviator with nearly two decades flying Citation light jets and a member of Textron Aviation’s Customer Advisory Board—helped shape the enhancements that elevate the CJ3 Gen2 experience. Key upgrades include Garmin autothrottle technology, added pilot legroom and a fully customizable cabin environment, all driven by customer feedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108455097/en/ Cessna Citation CJ3 Gen2 enters into service, delivering the most significant Gen2 updates to date (Photo credit: Textron Aviation). The Cessna Citation CJ3 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The Citation CJ3 Gen2 deliv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom